化療市場－全球產業規模、佔有率、趨勢、機會和預測，按類型、適應症、劑型、給藥途徑、最終用戶、地區和競爭細分，2020-2030 年預測

2024 年全球化療市場價值為 82.6 億美元，預計在預測期內將呈現令人印象深刻的成長，到 2030 年的複合年成長率為 8.51%。世界衛生組織 (WHO) 表示，癌症是全球第二大死因，2018 年造成約 960 萬人死亡。鑑於癌症發生率的上升，對化療藥物的需求將會增加。化療是一種癌症治療方法，它利用強效化學物質瞄準並消除體內快速分裂的細胞。它已被證明能減少癌細胞數量、阻止癌症進展和縮小腫瘤。例如，根據 WHO 2025，國際癌症研究機構 (IARC) 報告全球癌症負擔上升，服務不足的人受影響最大。一項針對 115 個國家的調查顯示，大多數國家沒有在全民健康覆蓋範圍內為優先癌症和安寧療護提供足夠的資金。研究結果強調了透過加強衛生系統投資來解決全球癌症治療不平等問題的迫切需求。

化療通常是單獨或合併使用，是一種適用於多種癌症的多功能治療方式。它可作為主要或唯一治療手段，清除隱藏的癌細胞，並為患者接受放射治療或手術等其他干預措施做好準備。化療還可以透過選擇性靶向癌細胞來緩解癌症相關的徵兆和症狀。

關鍵市場促進因素

癌症發生率上升

主要市場挑戰

治療費用高昂

主要市場趨勢

創新技術開發

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球化療市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按類型（烷化劑、抗代謝物、抗腫瘤抗生素、荷爾蒙、單株抗體、其他）
  • 依適應症（腫瘤/癌症、骨髓疾病類型、免疫系統疾病、其他）
  • 按劑型（膠囊、錠劑、注射劑、其他）
  • 依給藥途徑（口服、腸胃外、其他）
  • 按最終使用者（醫院、專科診所、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美化療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲化療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第8章：亞太化療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美洲化療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東與非洲化療市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 近期發展
• 併購

第 13 章：全球化療市場：SWOT 分析

第 14 章：競爭格局

• F. Hoffmann-La Roche Ltd.
• Mylan NV
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• Bayer AG
• Eli Lilly and Company
• Merck & Co., Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

Global Chemotherapy Market was valued at USD 8.26 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.51% through 2030. Cancer, as stated by the World Health Organization (WHO), is the second leading cause of mortality worldwide, resulting in an estimated 9.6 million deaths in 2018. Given the rising cancer rates, there will be an increased demand for chemotherapy medications. Chemotherapy is a cancer treatment approach that utilizes potent chemicals to target and eliminate rapidly dividing cells within the body. It has proven efficacy in reducing cancer cell count, impeding cancer progression, and shrinking tumors. For instance, according to WHO 2025, the International Agency for Research on Cancer (IARC) reported a rising global cancer burden, with underserved populations most affected. A survey across 115 countries revealed that most do not adequately fund priority cancer and palliative care within universal health coverage. The findings underscore the urgent need to address cancer care inequities worldwide through stronger health system investments.

Chemotherapy, often administered alone or in combination, is a versatile treatment modality for a wide range of cancers. It serves as a primary or sole treatment, eliminating hidden cancer cells and preparing patients for other interventions such as radiation or surgery. It can be employed to alleviate cancer-related signs and symptoms by selectively targeting cancer cells.

Key Market Drivers

Rising Incidences of Cancers

The increasing prevalence of cancer is projected to drive the growth rate of the chemotherapy drug market. According to NIH 2025, incidence rates of certain cancers have risen among individuals under age 50. However, despite this increase, overall cancer-related deaths in younger populations have not shown a corresponding rise. This suggests improvements in early detection, treatment options, and awareness, highlighting the importance of continued research and personalized care for younger cancer patients. Chemotherapy, often used in conjunction with other cancer treatments, remains the predominant approach to cancer treatment. Neo-adjuvant chemotherapy refers to chemotherapy administered prior to surgery and radiation therapy to reduce tumor size, while adjuvant chemotherapy is administered after surgery or radiation therapy to further shrink the tumor.

Key Market Challenges

High Cost of Treatment

The high cost associated with chemotherapy drugs poses a significant obstacle to the growth of the market. High chemotherapy costs can create financial barriers for patients, leading to delayed or deferred treatment, non-adherence to prescribed regimens, and reduced treatment effectiveness. Patients with limited financial resources may face disparities in accessing chemotherapy treatments, exacerbating existing healthcare inequalities. High costs can influence patients' treatment decisions, potentially leading to suboptimal choices based on financial considerations rather than medical necessity. The financial strain of chemotherapy can lead to reduced treatment access, particularly for uninsured or underinsured patients. The shortage of skilled professionals and inadequate healthcare infrastructure in developing economies present challenges to the chemotherapy drug market. The side effects of these drugs, including heart problems, decreased red blood cell count, fatigue, weight loss, hair loss, diarrhea, reduced lung, kidney, and liver function, decreased bone density, and limited awareness among the public, act as restraints and further hinder the market.

Key Market Trends

Development of Innovative Technology

Chemotherapy has played a pivotal role in extending the lifespan of cancer patients, surpassing their expected survival by several years. The latest breakthrough in the field of chemotherapy involves the administration of specially designed nanoparticles containing cancer-fighting medications, which selectively target affected areas while sparing healthy cells. This innovative approach has demonstrated remarkable efficacy in eradicating malignant cells while preserving surrounding healthy tissue. By utilizing photon lasers, medical professionals are able to precisely monitor the release, duration, and distribution of these medication-loaded nanoparticles within the patient's body. Excitingly, the University of California, Los Angeles, is currently conducting a clinical trial to evaluate the effectiveness of this approach, which has shown promising outcomes in the treatment of early-stage cancer patients. With its imminent entry into the chemotherapeutic market, this groundbreaking technique holds great potential for transforming cancer treatment.

Key Market Players

• Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• Bayer AG
• Eli Lilly and Company
• Merck & Co., Inc.

Report Scope:

In this report, the Global Chemotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chemotherapy Market, By Type:

• Alkylating Agents
• Anti-metabolites
• Anti-Tumor Antibiotics
• Hormones
• Monoclonal Antibodies
• Others

Chemotherapy Market, By Indication:

• Oncology/Cancer
• Bone Marrow Diseases
• Immune System Disorders
• Others

Chemotherapy Market, By Dosage Form:

• Capsule
• Tablets
• Injections
• Others

Chemotherapy Market, By Route of Administration:

• Oral
• Parenteral
• Others

Chemotherapy Market, By End User:

• Hospitals
• Specialty Clinics
• Others

Chemotherapy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chemotherapy Market.

Available Customizations:

Global Chemotherapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chemotherapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Alkylating Agents, Anti-metabolites, Anti-Tumor Antibiotics, Hormones, Monoclonal Antibodies, Others)
  • 5.2.2. By Indication (Oncology/Cancer, Bone Marrow Diseasestype, Immune System Disorders, Others)
  • 5.2.3. By Dosage Form (Capsule, Tablets, Injections, Others)
  • 5.2.4. By Route of Administration (Oral, Parenteral, Others)
  • 5.2.5. By End User (Hospitals, Specialty Clinics, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Chemotherapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Indication
  • 6.2.3. By Dosage Form
  • 6.2.4. By Route of Administration
  • 6.2.5. By End Users
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Chemotherapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Dosage Form
      • 6.3.1.2.4. By Route of Administration
      • 6.3.1.2.5. By End Users
  • 6.3.2. Canada Chemotherapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Dosage Form
      • 6.3.2.2.4. By Route of Administration
      • 6.3.2.2.5. By End Users
  • 6.3.3. Mexico Chemotherapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Dosage Form
      • 6.3.3.2.4. By Route of Administration
      • 6.3.3.2.5. By End Users

7. Europe Chemotherapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Indication
  • 7.2.3. By Dosage Form
  • 7.2.4. By Route of Administration
  • 7.2.5. By End Users
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Chemotherapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Dosage Form
      • 7.3.1.2.4. By Route of Administration
      • 7.3.1.2.5. By End Users
  • 7.3.2. United Kingdom Chemotherapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Dosage Form
      • 7.3.2.2.4. By Route of Administration
      • 7.3.2.2.5. By End Users
  • 7.3.3. Italy Chemotherapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Dosage Form
      • 7.3.3.2.4. By Route of Administration
      • 7.3.3.2.5. By End Users
  • 7.3.4. France Chemotherapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Dosage Form
      • 7.3.4.2.4. By Route of Administration
      • 7.3.4.2.5. By End Users
  • 7.3.5. Spain Chemotherapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Dosage Form
      • 7.3.5.2.4. By Route of Administration
      • 7.3.5.2.5. By End Users

8. Asia-Pacific Chemotherapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Indication
  • 8.2.3. By Dosage Form
  • 8.2.4. By Route of Administration
  • 8.2.5. By End Users
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Chemotherapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Dosage Form
      • 8.3.1.2.4. By Route of Administration
      • 8.3.1.2.5. By End Users
  • 8.3.2. India Chemotherapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Dosage Form
      • 8.3.2.2.4. By Route of Administration
      • 8.3.2.2.5. By End Users
  • 8.3.3. Japan Chemotherapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Dosage Form
      • 8.3.3.2.4. By Route of Administration
      • 8.3.3.2.5. By End Users
  • 8.3.4. South Korea Chemotherapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Dosage Form
      • 8.3.4.2.4. By Route of Administration
      • 8.3.4.2.5. By End Users
  • 8.3.5. Australia Chemotherapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Dosage Form
      • 8.3.5.2.4. By Route of Administration
      • 8.3.5.2.5. By End Users

9. South America Chemotherapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Indication
  • 9.2.3. By Dosage Form
  • 9.2.4. By Route of Administration
  • 9.2.5. By End Users
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Chemotherapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Dosage Form
      • 9.3.1.2.4. By Route of Administration
      • 9.3.1.2.5. By End Users
  • 9.3.2. Argentina Chemotherapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Dosage Form
      • 9.3.2.2.4. By Route of Administration
      • 9.3.2.2.5. By End Users
  • 9.3.3. Colombia Chemotherapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Dosage Form
      • 9.3.3.2.4. By Route of Administration
      • 9.3.3.2.5. By End Users

10. Middle East and Africa Chemotherapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Indication
  • 10.2.3. By Dosage Form
  • 10.2.4. By Route of Administration
  • 10.2.5. By End Users
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Chemotherapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Dosage Form
      • 10.3.1.2.4. By Route of Administration
      • 10.3.1.2.5. By End Users
  • 10.3.2. Saudi Arabia Chemotherapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Dosage Form
      • 10.3.2.2.4. By Route of Administration
      • 10.3.2.2.5. By End Users
  • 10.3.3. UAE Chemotherapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Dosage Form
      • 10.3.3.2.4. By Route of Administration
      • 10.3.3.2.5. By End Users

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions

13. Global Chemotherapy Market: SWOT Analysis

14. Competitive Landscape

• 14.1. F. Hoffmann-La Roche Ltd.
• 14.2. Mylan N.V.
• 14.3. Teva Pharmaceutical Industries Ltd.
• 14.4. Sanofi
• 14.5. Pfizer Inc.
• 14.6. GlaxoSmithKline plc
• 14.7. Novartis AG
• 14.8. Bayer AG
• 14.9. Eli Lilly and Company
• 14.10. Merck & Co., Inc.

15. Strategic Recommendations

16. About Us & Disclaimer